Laboratoire des Radiopharmaceutiques Bioclinique, INSERM 1039, Grenoble, France.
Circ Res. 2012 Mar 30;110(7):927-37. doi: 10.1161/CIRCRESAHA.112.265140.
A noninvasive tool allowing the detection of vulnerable atherosclerotic plaques is highly needed. By combining nanomolar affinities and fast blood clearance, nanobodies represent potential radiotracers for cardiovascular molecular imaging. Vascular cell adhesion molecule-1 (VCAM1) constitutes a relevant target for molecular imaging of atherosclerotic lesions.
We aimed to generate, radiolabel, and evaluate anti-VCAM1 nanobodies for noninvasive detection of atherosclerotic lesions.
Ten anti-VCAM1 nanobodies were generated, radiolabeled with technetium-99m, and screened in vitro on mouse and human recombinant VCAM1 proteins and endothelial cells and in vivo in apolipoprotein E-deficient (ApoE(-/-)) mice. A nontargeting control nanobody was used in all experiments to demonstrate specificity. All nanobodies displayed nanomolar affinities for murine VCAM1. Flow cytometry analyses using human human umbilical vein endothelial cells indicated murine and human VCAM1 cross-reactivity for 6 of 10 nanobodies. The lead compound cAbVCAM1-5 was cross-reactive for human VCAM1 and exhibited high lesion-to-control (4.95±0.85), lesion-to-heart (8.30±1.11), and lesion-to-blood ratios (4.32±0.48) (P<0.05 versus control C57Bl/6J mice). Aortic arch atherosclerotic lesions of ApoE(-/-) mice were successfully identified by single-photon emission computed tomography imaging. (99m)Tc-cAbVCAM1-5 binding specificity was demonstrated by in vivo competition experiments. Autoradiography and immunohistochemistry further confirmed cAbVCAM1-5 uptake in VCAM1-positive lesions.
The (99m)Tc-labeled, anti-VCAM1 nanobody cAbVCAM1-5 allowed noninvasive detection of VCAM1 expression and displayed mouse and human cross-reactivity. Therefore, this study demonstrates the potential of nanobodies as a new class of radiotracers for cardiovascular applications. The nanobody technology might evolve into an important research tool for targeted imaging of atherosclerotic lesions and has the potential for fast clinical translation.
需要一种非侵入性的工具来检测易损的动脉粥样硬化斑块。纳米抗体具有纳摩尔亲和力和快速血液清除率,是心血管分子成像的潜在放射性示踪剂。血管细胞黏附分子-1(VCAM1)是动脉粥样硬化病变分子成像的一个相关靶点。
我们旨在生成、放射性标记抗-VCAM1 纳米抗体,并评估其用于检测动脉粥样硬化病变的非侵入性。
生成了 10 种抗-VCAM1 纳米抗体,用锝-99m 放射性标记,并在体外筛选小鼠和人重组 VCAM1 蛋白和内皮细胞,以及在载脂蛋白 E 缺陷(ApoE(-/-))小鼠体内筛选。所有实验均使用非靶向对照纳米抗体来证明特异性。所有纳米抗体对鼠 VCAM1 的亲和力均达到纳摩尔水平。使用人脐静脉内皮细胞的流式细胞术分析表明,10 种纳米抗体中的 6 种对人 VCAM1 具有交叉反应性。先导化合物 cAbVCAM1-5 对人 VCAM1 具有交叉反应性,显示出高病变与对照(4.95±0.85)、病变与心脏(8.30±1.11)和病变与血液(4.32±0.48)的比值(P<0.05 与对照 C57Bl/6J 小鼠相比)。单光子发射计算机断层扫描成像成功地识别了 ApoE(-/-)小鼠主动脉弓动脉粥样硬化病变。(99m)Tc-cAbVCAM1-5 的结合特异性通过体内竞争实验得到证实。放射自显影和免疫组织化学进一步证实了 cAbVCAM1-5 在 VCAM1 阳性病变中的摄取。
(99m)Tc 标记的抗-VCAM1 纳米抗体 cAbVCAM1-5 允许非侵入性地检测 VCAM1 的表达,并显示出鼠与人的交叉反应性。因此,本研究证明了纳米抗体作为心血管应用的新型放射性示踪剂的潜力。纳米抗体技术可能发展成为靶向动脉粥样硬化病变成像的重要研究工具,并且具有快速临床转化的潜力。